Edison Issues ADR Update on GW Pharmaceuticals

News provided by

Feb 25, 2016, 10:07 ET

LONDON, February 25, 2016 /PRNewswire/ --

\With four Phase III trials of Epidiolex (cannabidiol, or CBD) in various forms of pediatric epilepsy, two for Dravet syndrome and two for Lennox-Gastaut syndrome (LGS) expected to provide top-line readouts in 2016 (three in H116), investors are understandably laser focused on these programs. Based on an analysis of the previous results of other molecules in Dravet and LGS, as well as data from the expanded access program, we are confident the trials are sufficiently powered to demonstrate a statistically significant benefit for patients taking Epidiolex.

(Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

Our valuation is now $2.04bn or $93.64/share (vs $1.83bn, $92.41/share) after increasing the probability of success for Epidiolex in Dravet and LGS to 70% from 50%, for schizophrenia to 25% from 20% and adding TSC and IV GWP42003 for NHIE to our model. This was mitigated by the removal of estimates for Sativex for cancer pain and GWP42003 for ulcerative colitis due to the failure of the programs.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website http://www.edisoninvestmentresearch.com.

About Edison: We are an international equity advisory firm. We enable our client companies to achieve their capital market objectives. The team is made up of more than 80 analysts and investment professionals with many decades of experience. Our extensive company knowledge and industry expertise spans 10 business sectors and more than 700 listed companies globally. We give our corporate clients and investors privileged insight into global investment trends. Our distribution capability is key to ensuring a global investor audience can access our investment knowledge. Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact:

Maxim Jacobs, Edison Investment Research, +1-646-653-7027

Nathaniel Calloway, Edison Investment Research, +1-646-653-7036, [email protected]

Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:

LinkedIn http://www.linkedin.com/company/edison-investment-research

Twitter: http://www.twitter.com/Edison_Inv_Res

YouTube: http://www.youtube.com/edisonitv

Google+: https://plus.google.com/105425025202328783163/posts

SOURCE Edison Investment Research